Astellas Pharma Inc (ALPMF) 12.0000 $ALPMF
Cytokinetics Announces Initiation of Multiple Dose Phase I Clinical Trial of CK-2127107
Thomson Reuters ONE - Thu Mar 27, 6:31AM CDT
Commencement of Study Triggers Milestone Payment from Astellas
Global Dermatological Drugs Market 2014-2018: The Global Dermatological Drugs Market is Expected to Reap Large Revenues with Increasing Use of Biologics
M2 - Wed Mar 26, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22gwrb/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide. The Global Dermatological Drugs market has also been witnessing a spurt in the use of biologics. However, the risk of adverse side effects associated with dermatological drugs could pose a challenge to the growth of this market. Key vendors dominating this space include AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., and Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA. Commenting on the report, an analyst from the team said: Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. For more information visit http://www.researchandmarkets.com/research/22gwrb/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Astellas Announces Marketing Approval in Japan for XTANDI® (enzalutamide) Capsules, an Advanced Prostate Cancer Treatment
PR Newswire - Mon Mar 24, 3:10PM CDT
Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI® capsules 40mg (development code: MDV3100; generic name: enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas filed the application for approval in Japan in May 2013.
Astellas and Medivation submits sNDA to the US FDA for XTANDI
M2 - Wed Mar 19, 7:26AM CDT
Japanese pharmaceutical company Astellas Pharma (TSE:4503) and US-based Medivation (NASDAQ:MDVN) reported on Tuesday the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for XTANDI capsules for treating men with metastatic castration-resistant prostate cancer (mCRPC) who have not undergone chemotherapy.
Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership
PR Newswire - Tue Mar 18, 11:30PM CDT
Astellas Pharma Inc. ("Astellas"; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company, Limited ("Daiichi Sankyo," President and CEO: Joji Nakayama) today announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds. The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library partnership of this scale has been formed in Japan.
Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naive Advanced Prostate Cancer
Marketwire - Tue Mar 18, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI(R) (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy.
American Urological Association And Astellas Team Up To Secure The Future Of Urology Research Through $3 Million Endowment
PR Newswire - Thu Mar 13, 9:00AM CDT
The American Urological Association (AUA) and Astellas US LLC, a U.S. affiliate of Tokyo-based Astellas Pharma Inc., have announced a $3 million commitment to the Urology Care Foundation and to the promising young urologists seeking careers in academic urology.
Research and Markets: Investigation Report on China's Tacrolimus Market, 2009-2018
Business Wire - Mon Mar 10, 11:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hcjjqn/investigation) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering.
Investigation Report on China's Tacrolimus Market, 2009-2018
M2 - Mon Mar 10, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qv9pgq/investigation) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering. Tacrolimus, also named as ""FK506"" and ""FR-900506"", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade name ""Prograf"". Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It was approved by the FDA in 1994. Tacrolimus is sold in markets of several countries and regions now. In 1998, tacrolimus preparation (injection and capsule) was approved to import into China. Since then, tacrolimus has become a first-line clinical drug to reduce organ rejection after liver and kidney transplantation in China. The sales revenue is also increasing rapidly. For immunosuppressant is used in transplantation, a relatively special field, it requires high technical standard and large amount of investment in new compound development. The drugs available at present are thus very monopolistic, among which tacrolimus is with the most promising future and highest market value. Since organ transplantation volume in China is only second to that of the U.S.A., a great amount of immunosuppressant is needed. The Chinese government has chosen this drug as clinical-preferred basic immunosuppressant. In recent years, the clinical application of tacrolimus continues to expand. It can treat many autoimmune diseases and is approved effective for immune diseases without specific medicine such as rheumatoid arthritis, kidney cirrhosis syndrome, atopic dermatitis and lupus. Therefore, the future is bright for medical use of tacrolimus. Key Topics Covered: 1 Relevant Concept of Tacrolimus 2 Market Overview of Tacrolimus in China 3 Investigation on Sales Value of Tacrolimus in China, 2009-2013 4 Investigation on Market Share of Major Tacrolimus Manufacturers in China, 2009-2013 5 Investigation on Market Size of Tacrolimus by Dosage Form in China, 2009-2013 6 Reference Price of Tacrolimus in Hospital Market in China, 2013 7 Major Manufacturing Enterprises in China Tacrolimus Market, 2009-2013 8 Prospect of China Tacrolimus Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/qv...estigation
Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results
PR Newswire - Tue Mar 04, 3:05PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2013 financial results. The Company also recently announced the acquisition of Vaprisol, a marketed critical care product from Astellas Pharma US, Inc.
Cumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US, Inc.
PR Newswire - Mon Mar 03, 7:05AM CST
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol® from Astellas Pharma US, Inc.
Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada
PR Newswire - Fri Feb 28, 6:00AM CST
Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea"). Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full responsibility for manufacturing isavuconazole in the U.S. and Canada.
Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America
GlobeNewswire - Fri Feb 28, 12:20AM CST
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the amendment as of February 27, 2014 of the isavuconazole License, Co-Development and Co-Promotion Agreement with Astellas Pharma Inc. originally executed in 2010, providing Basilea full rights to isavuconazole in all markets outside of the U.S. and Canada in return for Basilea's right to co-promote the product in the U.S. and Canada and its right to receive payments related to co-promotion and EU milestone payments.
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/lt4bvv/lupus_nephritis) has announced the addition of the "Lupus Nephritis Global Clinical Trials Review, H1, 2014" report to their offering. Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Lupus Nephritis Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials Latest Clinical Trials News on Lupus Nephritis Clinical Trial Profiles Clinical Trial Overview of Top Companies Clinical Trial Overview of Novartis AG Clinical Trial Overview of Astellas Pharma Inc. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Clinical Trial Overview of Biogen Idec Inc. Clinical Trial Overview of Anthera Pharmaceuticals Inc. Clinical Trial Overview of Teva Pharmaceutical Industries Limited Clinical Trial Overview of La Jolla Pharmaceutical Company Clinical Trial Overview of E. Merck KG Clinical Trial Overview of Bristol-Myers Squibb Company Clinical Trial Overview of Aurinia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government Clinical Trial Overview of Nanjing University Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Trial Overview of Sun Yat-sen University Clinical Trial Overview of Faculty of Pharmaceutical Sciences, Chulalongkorn University Clinical Trial Overview of Chinese University of Hong Kong Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of All India Institute of Medical Sciences Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases Clinical Trial Overview of Zhejiang University Clinical Trial Overview of The Rogosin Institute Five Key Clinical Profiles Appendix For more information visit http://www.researchandmarkets.com/research/lt..._nephritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MEDA: Year-End Report January-december 2013
Business Wire - Wed Feb 19, 1:12AM CST
Regulatory News:
Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
AVEO Oncology & Astellas Pharma Inc to terminate worldwide collaboration & license agreement for tivozanib and discontinue Phase 2 BATON study for colorectal cancer
M2 - Mon Feb 17, 6:21AM CST
Cancer therapeutics company AVEO Oncology (NasdaqGS:AVEO) said on Friday that it will end its worldwide collaboration and license agreement for the development and commercialisation of investigational agent tivozanib with Astellas Pharma Inc (TSE:4503) in August.
Announcement of Intention to Privatize and Invitation to Express Interest
PR Newswire - Thu Feb 13, 4:31AM CST
The Government of the Republic of Chad formally announces its intention to partially privatize the Société des Télécommunications du Tchad ("Groupe SOTEL Tchad") pursuant to the terms of law 004/PR/96. The Ministry of Commerce and Industry hereby invites interested parties to express interest to acquire a majority of the shares of SOTEL
Cytokinetics Announces Initiation of Multiple Dose Phase I Clinical Trial of CK-2127107
Thomson Reuters ONE - Thu Mar 27, 6:31AM CDT
Commencement of Study Triggers Milestone Payment from Astellas
Global Dermatological Drugs Market 2014-2018: The Global Dermatological Drugs Market is Expected to Reap Large Revenues with Increasing Use of Biologics
M2 - Wed Mar 26, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22gwrb/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide. The Global Dermatological Drugs market has also been witnessing a spurt in the use of biologics. However, the risk of adverse side effects associated with dermatological drugs could pose a challenge to the growth of this market. Key vendors dominating this space include AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., and Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA. Commenting on the report, an analyst from the team said: Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. For more information visit http://www.researchandmarkets.com/research/22gwrb/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Astellas Announces Marketing Approval in Japan for XTANDI® (enzalutamide) Capsules, an Advanced Prostate Cancer Treatment
PR Newswire - Mon Mar 24, 3:10PM CDT
Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI® capsules 40mg (development code: MDV3100; generic name: enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas filed the application for approval in Japan in May 2013.
Astellas and Medivation submits sNDA to the US FDA for XTANDI
M2 - Wed Mar 19, 7:26AM CDT
Japanese pharmaceutical company Astellas Pharma (TSE:4503) and US-based Medivation (NASDAQ:MDVN) reported on Tuesday the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for XTANDI capsules for treating men with metastatic castration-resistant prostate cancer (mCRPC) who have not undergone chemotherapy.
Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership
PR Newswire - Tue Mar 18, 11:30PM CDT
Astellas Pharma Inc. ("Astellas"; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company, Limited ("Daiichi Sankyo," President and CEO: Joji Nakayama) today announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds. The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library partnership of this scale has been formed in Japan.
Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naive Advanced Prostate Cancer
Marketwire - Tue Mar 18, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI(R) (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy.
American Urological Association And Astellas Team Up To Secure The Future Of Urology Research Through $3 Million Endowment
PR Newswire - Thu Mar 13, 9:00AM CDT
The American Urological Association (AUA) and Astellas US LLC, a U.S. affiliate of Tokyo-based Astellas Pharma Inc., have announced a $3 million commitment to the Urology Care Foundation and to the promising young urologists seeking careers in academic urology.
Research and Markets: Investigation Report on China's Tacrolimus Market, 2009-2018
Business Wire - Mon Mar 10, 11:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hcjjqn/investigation) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering.
Investigation Report on China's Tacrolimus Market, 2009-2018
M2 - Mon Mar 10, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qv9pgq/investigation) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering. Tacrolimus, also named as ""FK506"" and ""FR-900506"", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade name ""Prograf"". Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It was approved by the FDA in 1994. Tacrolimus is sold in markets of several countries and regions now. In 1998, tacrolimus preparation (injection and capsule) was approved to import into China. Since then, tacrolimus has become a first-line clinical drug to reduce organ rejection after liver and kidney transplantation in China. The sales revenue is also increasing rapidly. For immunosuppressant is used in transplantation, a relatively special field, it requires high technical standard and large amount of investment in new compound development. The drugs available at present are thus very monopolistic, among which tacrolimus is with the most promising future and highest market value. Since organ transplantation volume in China is only second to that of the U.S.A., a great amount of immunosuppressant is needed. The Chinese government has chosen this drug as clinical-preferred basic immunosuppressant. In recent years, the clinical application of tacrolimus continues to expand. It can treat many autoimmune diseases and is approved effective for immune diseases without specific medicine such as rheumatoid arthritis, kidney cirrhosis syndrome, atopic dermatitis and lupus. Therefore, the future is bright for medical use of tacrolimus. Key Topics Covered: 1 Relevant Concept of Tacrolimus 2 Market Overview of Tacrolimus in China 3 Investigation on Sales Value of Tacrolimus in China, 2009-2013 4 Investigation on Market Share of Major Tacrolimus Manufacturers in China, 2009-2013 5 Investigation on Market Size of Tacrolimus by Dosage Form in China, 2009-2013 6 Reference Price of Tacrolimus in Hospital Market in China, 2013 7 Major Manufacturing Enterprises in China Tacrolimus Market, 2009-2013 8 Prospect of China Tacrolimus Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/qv...estigation
Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results
PR Newswire - Tue Mar 04, 3:05PM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2013 financial results. The Company also recently announced the acquisition of Vaprisol, a marketed critical care product from Astellas Pharma US, Inc.
Cumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US, Inc.
PR Newswire - Mon Mar 03, 7:05AM CST
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol® from Astellas Pharma US, Inc.
Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada
PR Newswire - Fri Feb 28, 6:00AM CST
Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea"). Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full responsibility for manufacturing isavuconazole in the U.S. and Canada.
Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America
GlobeNewswire - Fri Feb 28, 12:20AM CST
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the amendment as of February 27, 2014 of the isavuconazole License, Co-Development and Co-Promotion Agreement with Astellas Pharma Inc. originally executed in 2010, providing Basilea full rights to isavuconazole in all markets outside of the U.S. and Canada in return for Basilea's right to co-promote the product in the U.S. and Canada and its right to receive payments related to co-promotion and EU milestone payments.
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report
M2 - Mon Feb 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/lt4bvv/lupus_nephritis) has announced the addition of the "Lupus Nephritis Global Clinical Trials Review, H1, 2014" report to their offering. Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: List of Tables List of Figures Introduction Lupus Nephritis Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials Latest Clinical Trials News on Lupus Nephritis Clinical Trial Profiles Clinical Trial Overview of Top Companies Clinical Trial Overview of Novartis AG Clinical Trial Overview of Astellas Pharma Inc. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Clinical Trial Overview of Biogen Idec Inc. Clinical Trial Overview of Anthera Pharmaceuticals Inc. Clinical Trial Overview of Teva Pharmaceutical Industries Limited Clinical Trial Overview of La Jolla Pharmaceutical Company Clinical Trial Overview of E. Merck KG Clinical Trial Overview of Bristol-Myers Squibb Company Clinical Trial Overview of Aurinia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government Clinical Trial Overview of Nanjing University Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases Clinical Trial Overview of Sun Yat-sen University Clinical Trial Overview of Faculty of Pharmaceutical Sciences, Chulalongkorn University Clinical Trial Overview of Chinese University of Hong Kong Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases Clinical Trial Overview of All India Institute of Medical Sciences Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases Clinical Trial Overview of Zhejiang University Clinical Trial Overview of The Rogosin Institute Five Key Clinical Profiles Appendix For more information visit http://www.researchandmarkets.com/research/lt..._nephritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MEDA: Year-End Report January-december 2013
Business Wire - Wed Feb 19, 1:12AM CST
Regulatory News:
Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
AVEO Oncology & Astellas Pharma Inc to terminate worldwide collaboration & license agreement for tivozanib and discontinue Phase 2 BATON study for colorectal cancer
M2 - Mon Feb 17, 6:21AM CST
Cancer therapeutics company AVEO Oncology (NasdaqGS:AVEO) said on Friday that it will end its worldwide collaboration and license agreement for the development and commercialisation of investigational agent tivozanib with Astellas Pharma Inc (TSE:4503) in August.
Announcement of Intention to Privatize and Invitation to Express Interest
PR Newswire - Thu Feb 13, 4:31AM CST
The Government of the Republic of Chad formally announces its intention to partially privatize the Société des Télécommunications du Tchad ("Groupe SOTEL Tchad") pursuant to the terms of law 004/PR/96. The Ministry of Commerce and Industry hereby invites interested parties to express interest to acquire a majority of the shares of SOTEL
